News
CTSO
0.8200
-0.21%
-0.0017
Weekly Report: what happened at CTSO last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at CTSO last week (0408-0412)?
Weekly Report · 04/15 11:09
Weekly Report: what happened at CTSO last week (0401-0405)?
Weekly Report · 04/08 11:14
CytoSorbents Executives Take Pay Cuts for Stock Options
TipRanks · 04/03 10:24
CYTOSORBENTS CORP - REDUCED BASE SALARY IS EFFECTIVE FOR THE PERIOD OF APRIL 1, 2024 THROUGH DECEMBER 31, 2024
Reuters · 04/03 10:07
CYTOSORBENTS- PHILLIP P. CHAN (CEO), KATHLEEN P. BLOCH (CFO), AMONG EXECUTIVES WHO CHOSE TO PARTICIPATE IN VOLUNTARY SALARY REDUCTION PROGRAM
Reuters · 04/03 10:07
CYTOSORBENTS CORP - PURSUANT TO THE SALARY REDUCTION AGREEMENTS, THE CEO AGREED TO REDUCE HIS BASE SALARY BY 35%
Reuters · 04/03 10:07
Weekly Report: what happened at CTSO last week (0325-0329)?
Weekly Report · 04/01 11:12
Weekly Report: what happened at CTSO last week (0318-0322)?
Weekly Report · 03/25 11:15
Weekly Report: what happened at CTSO last week (0311-0315)?
Weekly Report · 03/18 11:13
Cytosorbents Price Target Maintained With a $1.00/Share by HC Wainwright & Co.
Dow Jones · 03/15 10:50
HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
Benzinga · 03/15 10:40
Cytosorbents Financial and Clinical Study Outlook: Maintaining a Hold Rating
TipRanks · 03/15 10:27
CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023
CytoSorbents reported earnings per share of -12 cents. The company reported revenue of $8.70 million. This was 6.25% worse than the analyst estimate for the company to report revenue of -10 million. The stock was down 2.7% after the market closed.
Investorplace · 03/15 01:53
Cytosorbents Corp reports results for the quarter ended in December - Earnings Summary
Cytosorbents Corp reports results for the quarter ended in December. Revenue fell 7.7% to $8.67 million from a year ago. The company reported a quarterly adjusted loss of 13 cents per share. The mean expectation of four analysts was for a loss of 14 cents.
Reuters · 03/14 23:20
Press Release: CytoSorbents Reports Fourth -4-
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids. The Company's technologies have received non-dilutive funding of approximately $50 million from DARPA.
Dow Jones · 03/14 20:39
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
Notable earnings after Thursday's close
Major earnings expected after the bell on Thursday include: Adobe, Ulta Beauty, Skillz and Wheaton Precious Metals Corp. Other notable earnings slated for release after Thursday's close include: ZUMZ, ULTA and Blink Charging Co. Other companies with major earnings scheduled after the close of business on Thursday.
Seeking Alpha · 03/13 21:35
A Preview Of CytoSorbents's Earnings
CytoSorbents is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Analysts estimate the company will report an earnings per share of $-0.14. Last quarter the company missed EPS by $0.09 and shares are down 68.81% in the last 52 weeks.
Benzinga · 03/13 16:01
Weekly Report: what happened at CTSO last week (0304-0308)?
Weekly Report · 03/11 11:10
More
Webull provides a variety of real-time CTSO stock news. You can receive the latest news about Cytosorbents Corp through multiple platforms. This information may help you make smarter investment decisions.
About CTSO
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.